Clinical and immunological comparisons of the results of testing for COVID-19 of employees of an outpatient medical organization of a large industrial centre during a pandemic
-
Published:2021-01-17
Issue:4
Volume:15
Page:161-167
-
ISSN:2413-0958
-
Container-title:South of Russia: ecology, development
-
language:
-
Short-container-title:Ûg Ross.: èkol. razvit.
Author:
Obukhova O. O.1ORCID, Trunov A. N.1ORCID, Gorbenko O. M.1ORCID, Shvayuk A. P.1ORCID, Ryabichenko T. I.1ORCID, Skosyreva G A.1ORCID, Obukhov A. V.2ORCID
Affiliation:
1. Federal Research Centre of Fundamental and Translational Medicine 2. City Clinical Polyclinic №13
Abstract
Aim. To determine the presence or absence of specific IgG antibodies against SARS-CoV-2 antigens in outpatient clinic staff and to compare clinical and immunological features from April to August 2020.Materials and Methods. The control group comprised 386 employees of the Novosibirsk City Clinical Polyclinic №13.The determination of IgG antibodies against SARS-CoV-2 antigens in blood serum was performed by using the ELISA method. A real time method of reverse transcription and polymerase chain reaction was used to extract RNA SARS-CoV-2 from nasopharyngeal and oropharyngeal swabs.Results. Specific IgG antibodies against SARS-CoV-2 antigens were detected in 32 (8.42%) employees of the polyclinic. Antibodies were not detected in 91.58% of employees. 9 members (28.12%) had clinical symptoms of varying degrees of disease severity in the group of employees with the presence of antibodies, 4 members of this group (12,51%) had bilateral community-acquired pneumonia with signs of COVID infection, another 5 members (15.61%) with antibodies had signs of ARVI of mild and moderate severity. RNA SARS-CoV-2 in the group of employees with the presence of antibodies and clinical implications was not detected in any case; 23 (71.88%) members with the presence of IgG-antibodies did not have clinical implications of the disease.Conclusion. The presence of specific antibodies against SARS-CoV-2 in employees with clinical implications of COVID-19 without detection of the RNA virus in the biological material is a retrospective confirmation of the etiology of the transferred infection. The detection of specific antibodies in persons who did not have clinical implications can serve as confirmation of the asymptomatic course of the transferred coronavirus infection.
Publisher
Institute of Applied Ecology
Subject
Ecology,Geography, Planning and Development,Ecology, Evolution, Behavior and Systematics
Reference19 articles.
1. I. Litvinov A.S., Savin A.V., Kuhtina A.A. Long-term prospects for extrapulmonary persistence of SARS-CoV-2 coronavirus. Medicine, 2020, vol. 8, no. 1, pp. 51-73. (In Russian) DOI: 10.29234/2308-9113-2020-8-1-51-73 2. Hofmann H., Pyrc K., van der Hoek L., Geier M., Berkhout B., Pohlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl Acad. Sci. USA, 2005, vol. 102, iss. 22, pp. 7988-7993. DOI: 10.1073/pnas.0409465102 3. Tisoncik J.R., Korth M., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm. Microbiology and Molecular Biology Reviews, 2012, vol. 76, no. 1, pp. 16-32. DOI: 10.1128/MMBR.05015-11 4. Zhang C., Wu Z., Li J.-W., Zhaoab H., Wang G.-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. International Journal of Antimicrobial Agents, 2020, vol. 55, iss. 5, 105954. DOI: 10.1016/j.ijantimicag.2020.105954 5. Giavridis T., van der Stegen S.J., Eyquem J., Hamieh M., Piersigilli A., Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med., 2018, vol. 24, no. 6, pp. 731738. DOI: 10.1038/s41591-018-0041-7
|
|